LANXESS Aktiengesellschaft · ISIN: DE0005470405 · EQS - adhoc news

LANXESS signs contract to sell Urethane Systems business to UBE Corporation

          Ad hoc according to Art. 17 paragraph 1 MAR LANXESS signs contract to sell Urethane Systems business for an enterprise value of €460 m to UBE Corporation - proceeds will be used to reduce net financial debt   Specialty chemicals company LANXESS signed a contract to sell its Urethane Systems business to UBE Corporation on 3rd October, 2024. The enterprise value amounts to €460 m with expected proceeds of around €500 m. With this transaction LANXESS exits the last remaining polymer ...

XETR:LXS Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News LANXESS Aktiengesellschaft

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (26)
Short Selling (DE) (42)
Short Selling (UK) (0)
03 October 2024 08:04AM
LANXESS signs contract to sell Urethane Systems business to UBE Corporation
DE0005470405
          Ad hoc according to Art. 17 paragraph 1 MAR LANXESS signs contract to sell Urethane Systems business for an enterprise value of €460 m to UBE Corporation - proceeds will be used to reduce net financial debt   Specialty chemicals company LANXESS signed a contract to sell its Urethane Systems business to UBE Corporation on 3rd October,...
LANXESS Aktiengesellschaft
About the publication
17 July 2024 01:58PM
EBITDA pre exceptionals for second quarter 2024 significantly above market expectations
DE0005470405
          Ad hoc according to Art. 17 paragraph 1 MAR LANXESS: EBITDA pre exceptionals for second quarter 2024 significantly above market expectation Specialty chemicals company LANXESS expects to achieve a second quarter 2024 EBITDA pre exceptionals that considerably exceeds average market expectation and previous year's level. The preliminary...
LANXESS Aktiengesellschaft
About the publication
27 February 2024 08:10PM
Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior
DE0005470405
           Ad hoc according to Art. 17 paragraph 1 MAR Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior During the preparation of annual financial statements for the year 2023, LANXESS identified an impairment requirement on goodwill amounting to EUR 413 million. The impairment incurred in the Busine...
LANXESS Aktiengesellschaft
About the publication
06 November 2023 11:42AM
LANXESS adjusts expectations for FY 2023; Board of Management proposes dividend reduction
DE0005470405
Ad hoc according to Art. 17 paragraph 1 MMVOLANXESS adjusts expectations for FY 2023; Board of Management proposes dividend reduction Demand in the fourth quarter for specialty chemical products of LANXESS is expected to be lower than estimated. Initiated destocking of customers in the agroindustry and a supplier-related production limitation for ...
LANXESS Aktiengesellschaft
About the publication
19 June 2023 07:32PM
Results for Q2 and FY 2023 estimated below market expectations
DE0005470405
          Ad hoc according to Art. 17 paragraph 1 MMVO   LANXESS: Results for Q2 and FY 2023 estimated below market expectations Specialty chemicals company LANXESS expects second quarter 2023 EBITDA pre exceptionals to remain below average market expectations. Therefore, the company adjusts the outlook for FY 2023 downward as well. EBITDA pre...
LANXESS Aktiengesellschaft
About the publication
19 June 2023 07:32PM
LANXESS Aktiengesellschaft: Results for Q2 and FY 2023 estimated below market expectations
DE0005470405
          Ad hoc according to Art. 17 paragraph 1 MMVO   LANXESS: Results for Q2 and FY 2023 estimated below market expectations Specialty chemicals company LANXESS expects second quarter 2023 EBITDA pre exceptionals to remain below average market expectations. Therefore, the company adjusts the outlook for FY 2023 downward as well. EBITDA pre...
LANXESS Aktiengesellschaft
About the publication
31 May 2022 08:02AM
LANXESS Aktiengesellschaft: LANXESS and Advent establish a leading global joint venture for high-performance plastics
DE0005470405
Ad hoc according to  Art. 17 paragraph 1 MMVOLANXESS and Advent International establish a leading global joint venture for high-performance engineering polymers LANXESS transfers High-Performance Materials business into joint venture LANXESS High Performance Materials business valued at EUR 2.5 billion. LANXESS receives a payment of at least EUR ...
LANXESS Aktiengesellschaft
About the publication
19 April 2022 08:01PM
LANXESS Aktiengesellschaft: Strong start into the year - first quarter 2022 expected to exceed market expectations
DE0005470405
Ad hoc according to Art. 17 paragraph 1 MMVO LANXESS Aktiengesellschaft: Strong start into the year - first quarter 2022 expected to exceed market expectations - Growth of EBITDA pre exceptionals of 32 percent expected compared to prior-year quarter - Expected EBITDA pre exceptionals of EUR 320 million around 7 percent above average market exp...
LANXESS Aktiengesellschaft
About the publication
24 August 2021 12:27AM
LANXESS Aktiengesellschaft: LANXESS signs contract to acquire Microbial Control business of IFF
DE0005470405
Ad hoc according to Art. 17 paragraph 1 MMVO LANXESS signs contract to acquire Microbial Control business of IFF Cologne, August 23, 2021 - Specialty chemicals company LANXESS has signed an agreement to acquire the microbial control business from the US-based company International Flavors & Fragrances Inc. (IFF). The acquisition will create o...
LANXESS Aktiengesellschaft
About the publication
26 January 2021 01:13PM
LANXESS Aktiengesellschaft: EBITDA pre exceptionals for fourth quarter 2020 estimated above market expectations
DE0005470405
Ad hoc according to Art. 17 paragraph 1 MMVO LANXESS Aktiengesellschaft: EBITDA pre exceptionals for fourth quarter 2020 estimated above market expectations Specialty chemicals company LANXESS expects to achieve fourth quarter 2020 EBITDA pre exceptionals that considerably exceeds average market expectations and previous year's level. EBITDA pre ex...
LANXESS Aktiengesellschaft
About the publication
More LANXESS Aktiengesellschaft related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 26 9th October 2024 Müller, Dr. Hans-Joachim DD
Short Seller (DE) 42 18th December 2024 Millennium Capital Partners LLP SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN